Lung Cancer Treatment Linked to Improved Survival Outcomes
Patients with specific KRAS mutations saw better response rates to a newer immunotherapy.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Do you trust that new medical trial results are applicable to the average patient?
In an exploratory analysis of the EMPOWER-Lung 1 trial, researchers found that patients with KRAS-mutated non-small cell lung cancer responded well to first-line treatment with cemiplimab. This finding offers new clinical data for those managing this specific lung cancer profile.
Why it matters
Patients with KRAS mutations have historically faced lower survival rates with chemotherapy alone, making the identification of effective alternative therapies a critical step in improving treatment standards. These results help clarify the potential benefit of targeting this specific mutation with immunotherapy.
An exploratory analysis of 89 patients from the EMPOWER-Lung 1 trial found that those with a KRAS mutation achieved a 67% response rate with cemiplimab. Median overall survival reached 53 months, while the KRAS G12C subgroup showed a 74% response rate and 25 months of progression-free survival.
The players
Perlmutter Cancer Center
A research institution at NYU Langone Health that studies advanced cancer therapies and clinical outcomes.
Sylvester Comprehensive Cancer Center
A facility at the University of Miami involved in complex cancer research and clinical trial development.
The details
Cemiplimab is an immunotherapy that works by blocking the PD-1 pathway, which allows the immune system to better identify and attack cancer cells. The trial focused on patients with PD-L1 expression of 50 percent or higher, excluding those with other specific genetic alterations like EGFR or ALK. By analyzing the subset of 89 patients with KRAS mutations, researchers evaluated how these specific biological markers respond when compared to traditional platinum-based chemotherapy regimens.
Timeline
September 30, 2026: Trial outcomes for cemiplimab were published.
Health Landscape
This analysis builds upon the foundation of the EMPOWER-Lung 1 trial to better understand how immunotherapy fits into the management of genetically defined lung cancers. It reflects a broader shift toward refining first-line treatment strategies based on specific mutation profiles rather than broad chemotherapy alone.
If you or a loved one are managing lung cancer with a known KRAS mutation, these results are worth discussing with an oncologist to understand how genetic markers influence current treatment options. Ask your medical team whether your PD-L1 expression levels or mutation status impact your eligibility for emerging immunotherapy protocols.
The takeaway
The study suggests that immunotherapy may offer a significant survival advantage for patients with specific KRAS-mutated lung cancers. Individuals should work with their oncology team to ensure that comprehensive genetic testing has been performed to guide their personal care plan.
Further reading
For more information on evolving treatment options, visit the Cancer section.
Source note: This article includes information reported by OncLive.
Live Poll
Do you trust that new medical trial results are applicable to the average patient?
